Extended Data Table 6 AAV9-Gabarapl1 T2D mice: systemic and cardiac characteristics

From: Targeted glycophagy ATG8 therapy reverses diabetic heart disease in mice and in human engineered cardiac tissues

  1. Related to Fig. 4&5. T2D mice (high fat diet-fed) injected with AAV9-cTnT-Null (AAV-Null) and AAV9-cTnT-Gabarapl1 (AAV-Gab) were assessed at 12 weeks post-AAV injection (i.v.) with 28 week diet feeding. Data presented as mean ± SEM and analyzed by 2-way ANOVA with Bonferroni post-hoc tests, *p < 0.05.
  2. Source Data
Back to article page